Molecular diagnosis of mast cell disorders - A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

被引:54
作者
Akin, Cem [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Allergy & Immunol, Ann Arbor, MI 48109 USA
关键词
D O I
10.2353/jmoldx.2006.060022
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Mastocytosis is a disease characterized by pathological mast cell accumulation and activation in tissues. Most patients with mastocytosis exhibit the D816V point mutation in the tyrosine kinase domain of the transmembrane receptor protein Kit, leading to its constitutive activation in bone marrow or lesional skin tissue. Detection of a codon 816 c-kit mutation is included as a minor diagnostic criterion in the World Health Organization's diagnostic criteria for systemic, mastocytosis. Determining mutational status of the c-kit gene also has pharmacogenomic implications in patients considered for investigational mast cell cytoreductive therapies. This article reviews diagnostic and therapeutic implications of c-kit mutations as well as other less common molecular abnormalities observed in mast cell disease.
引用
收藏
页码:412 / 419
页数:8
相关论文
共 57 条
  • [1] Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis
    Agis, H
    Sotlar, K
    Valent, P
    Horny, HP
    [J]. LEUKEMIA RESEARCH, 2005, 29 (10) : 1227 - 1232
  • [2] A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib
    Akin, C
    Fumo, G
    Yavuz, AS
    Lipsky, PE
    Neckers, L
    Metcalfe, DD
    [J]. BLOOD, 2004, 103 (08) : 3222 - 3225
  • [3] Systemic mastocytosis
    Akin, C
    Metcalfe, DD
    [J]. ANNUAL REVIEW OF MEDICINE, 2004, 55 : 419 - 432
  • [4] Clonality and molecular pathogenesis of mastocytosis
    Akin, C
    [J]. ACTA HAEMATOLOGICA, 2005, 114 (01) : 61 - 69
  • [5] The biology of Kit in disease and the application of pharmacogenetics
    Akin, C
    Metcalfe, DD
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (01) : 13 - 19
  • [6] Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
    Akin, C
    Brockow, K
    D'Ambrosio, C
    Kirshenbaum, AS
    Ma, YS
    Longley, BJ
    Metcalfe, DD
    [J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) : 686 - 692
  • [7] Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case?
    Akin, C
    Scott, LM
    Metcalfe, DD
    [J]. LEUKEMIA RESEARCH, 2001, 25 (07) : 635 - 638
  • [8] Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139
  • [9] Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
    Cairoli, R
    Beghini, A
    Grillo, G
    Nadali, G
    Elice, F
    Ripamonti, CB
    Colapietro, P
    Nichelatti, M
    Pezzetti, L
    Lunghi, M
    Cuneo, A
    Viola, A
    Ferrara, F
    Lazzarino, M
    Rodeghiero, F
    Pizzolo, G
    Larizza, L
    Morra, E
    [J]. BLOOD, 2006, 107 (09) : 3463 - 3468
  • [10] Chronic myelogenous leukemia with acquired c-kit activating mutation and transient bone marrow mastocytosis
    Cairoli, R
    Grillo, G
    Beghini, A
    Cornacchini, G
    Larizza, L
    Morra, E
    [J]. HEMATOLOGY JOURNAL, 2004, 5 (03) : 273 - 275